Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE)…
Source